51 results
Primary Objectives:* Identify the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D, 200mg BID) of TAS-119.
Primary Efficacy Objectives:The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of exposure to bexagliflozin in type 2 diabetic subjects with increased risk of cardiovascular…
Objective of the phase II POP study:To determine the safety and preliminary anti-tumor activity of AZD1775 in combination with carboplatin in p53 mutated epithelial ovarian cancer in a 21 day schedule.Objectives of the additional safety and…
To determine the effect of benralizumab on the rate of asthma exacerbationsSubstudy: - To assess the potential for benralizumab treated patients to reduce their standard of care asthma controller regimen whilemaintaining asthma control.- To assess…
To evaluate the efficacy and safety of T-817MA in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease.
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.
Primary: • To evaluate whether long-term treatment with bempedoic acid 180 mg/day versus placebo reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease (CVD) who are statin…
Primary• To evaluate the effect of CK-3773274 on exercise capacity (VO2) in patients with symptomatic oHCMSecondary• To evaluate the effect of CK-3773274 on patient health status• To evaluate the effect of CK-3773274 on New York Heart Association (…
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the study drug CT1812 in subjects with mild to moderate Alzheimer*s disease. The efficacy of CT1812 will be compared to the efficacy of a placebo. A placebo is a…
Primary ObjectivesParts 1 and 2: To evaluate the safety and tolerability, describe any dose-limiting toxicity (DLT), determine the maximum tolerated dose (MTD) or highest protocol- defined doses (in the absence of exceeding the MTD) and the…
Primary Objective: To evaluate the safety and efficacy of 2 concentrations of Atropine Sulfate OphthalmicSolution (0.01% and 0.02%) compared to Vehicle (placebo) for slowing the progression of myopia inchildren over a 3-year treatment period.…